¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ°£ÇÐȸ APASL STC 2023 DAY 2 : 2023-09-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ°£ÇÐȸ APASL STC 2023 DAY 2 : 2023-09-22
±³À°ÀÏÀÚ : 2023-09-22
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ ROOM 1~4

±³À°ÁÖÁ¦ : APASL STC 2023 DAY 2

ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL STC Áغñ»ç¹«±¹
¿¬¶ôó : 02-373-1005  

À̸ÞÀÏ : apaslstc2023@hbni.co.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 19 ½Ã°£ 10ºÐ

¼¼ºÎ¼ö°­·á : 320,000¿ø  

ºñ°í Early Bird Registration-APASL Member USD 100/Non-Member USD 150/Trainee / Resident / Researcher / Nurse USD 50/Abstract Presenting Author USD 50/Group (more than 10)USD 50 Regular Registration-APASL Member USD 150/Non-Member USD 200/Trainee / Resident / Researcher / Nurse USD 80/Abstract Presenting Author USD 50/Group (more than 10)USD 80


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 08:30~08:50 Ultra-High Sensitivity HBsAg and Anti-HBc in Managing Chronic Hepatitis B Jihyun An(Hanyang Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 08:50~09:10 HBcrAg and HBV RNA in Managing Chronic Hepatitis B Lung Yi Mak(The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 09:10~09:30 Circulating Virus-Host Chimera DNAs for Monitoring Virus-Related HCC Shiou-Hwei Yeh(National Taiwan Univ., Taiwan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 10:50~11:05 How to Manage Patients with Previous DAA Treatment Failure Young-Joo Jin(Inha Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:05~11:20 How to Manage Difficult-to-Cure Patients: Decompensated Disease and Transplantation In Hee Kim(Chonbuk National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:20~11:35 Managing Drug-Drug Interaction, Adherence, and Adverse Events in the Era of Pangenotypic DAA Woo Jin Chung(Keimyung Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 11:35~11:50 Multidisciplinary Approach to Predict Fibrosis Progression and HCC after DAA Therapy Tawesak Tanwandee(Mahidol Univ., Thailand)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 12:50~13:20 The Road to Curing Hepatitis B Virus Infection: Past, Present, and Future George Lau(Humanity and Health Medical Group, Hong Kong)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 13:20~13:40 Genetic Polymorphism (& Family History) as a Non-Modifiable Risk Factor for HCC after HBV Cure Yoon Jun Kim(Seoul National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 13:40~14:00 Viral Persistence after a Functional Cure of HBV and HCC Risk Jia-Horng Kao(National Taiwan Univ., Taiwan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 14:00~14:20 Molecular Mechanism of Hepatocarcinogenesis after SVR in Patients with HCV Raymond T. Chung(Harvard Univ. USA)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 14:40~15:00 Classification and Clinical Characteristics of Gray Zone in Chronic Hepatitis B Marc G. Ghany(NIH, USA)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:00~15:20 HBeAg-Positive "Gray-Zone": Should We Treat and Why? Tai-Chung Tseng(National Taiwan Univ., Taiwan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:20~15:40 HBeAg-Negative "Gray-Zone": Should We Treat and Why? Jordan Feld (Univ. of Toronto, Canada)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 15:40~16:00 Optimizing Non-Invasive Methods to Identify Gray-Zone Patients with Liver Fibrosis Seung Up Kim(Yonsei Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:20~16:35 Stopping Antivirals Wen-Juei Jeng(Chang Gung Univ., Taiwan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:35~16:50 Continuing Antivirals Jonggi Choi(Ulsan Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 16:50~17:05 Interferon or Interferon-Based Therapy Tarik Asselah(Hepatology at Hôpital Beaujon, France)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 1 17:05~17:20 Newer Antiviral Agents Robert Gish(The Univ. of Nevada, USA)

Åä·Ð 09¿ù 22ÀÏ ROOM 1 17:20~17:40 Panel Discussion ()

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 08:30~08:45 Liver and Spleen Stiffness for the Estimation of Portal Hypertension and Cirrhotic Complications Moonyoung Kim(Yonsei Univ. Wonju, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 08:45~09:00 Antiviral Therapy and the Outcome of Patients with Decompensated Cirrhosis Sung Eun Kim(Hallym Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:00~09:15 Optimal Assessment and Improving Survival in Acute Variceal Bleeding Shiv Kumar Sarin(Institute of Liver & Biliary Sciences, India)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:15~09:30 The Role of Antibiotic Therapy in Acute Decompensation Jung Gil Park(Yeungnam Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:30~09:45 Immunopathogenesis of Acute Hepatitis A Eui-Cheol Shin(KAIST, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 09:45~10:00 Novel Therapies for Hepatitis Delta (HDV) Young Eun Chon(CHA Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:00~10:15 Disease Burden and Potential Therapeutic Approach to HEV Infection Lubna Kamani Liaquat(National Hospital, Pakistan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:15~10:30 Pathogenesis and Management of Non-Hepatotropic Viruses Ju-Yeon Cho (Chosun Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 10:50~11:05 Role of Metabolic Risk Factors in the Outcome of Viral Hepatitis Lai Wei(Tsinghua Univ., China)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:05~11:20 Effects of Alcohol Drinking on the Prognosis of Patients with Viral Hepatitis Won Kim (Seoul National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:20~11:35 MAFLD in Chronic Hepatitis B: Friend or Foe? Lung Yi Mak (The Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 11:35~11:50 Management Strategies for Viral Hepatitis with Concurrent MAFLD Hye Won Lee (Yonsei Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 14:40~15:00 Anti-HBV Therapy to Prevent HBV-Associated HCC Tetsuya Hosaka(Toranomon Hospital, Japan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:00~15:20 Anti-HCV Therapy to Prevent HCV-Associated HCC Do Young Kim(Yonsei Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:20~15:40 Non-Viral Managements to Prevent HCC Dong Hyun Sinn (Sungkyunkwan Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 15:40~16:00 (Cost-Effective) Risk-Stratified Surveillance for Hepatitis Virus-Associated HCC Shuichiro Shiina(Juntendo Univ., Japan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 16:20~16:40 Developing AI Model for Predicting HCC Hwi Young Kim(Ewha Womans Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 16:40~17:00 Radiomics and Deep Learning for Chronic Liver Disease Roongruedee Chaiteerakij(Chulalongkorn Univ., Thailand)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 17:00~17:20 Harnessing Knowledge and Experimental Data Using AI Drug Discovery Technology Han Jo Kim(Standigm, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 2 17:20~17:40 Deep Learning-Based Prediction of Biomarkers Using Liver Cancer Histopathological Images Sung Hak Lee(The Catholic Univ. of Korea, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 07:30~07:42 Impact of Metabolic Factors on the Risk of HBV-Related HCC Yun Bin Lee(Seoul National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 07:42~07:54 Have Risk Factors for HCC Changed over the Decades? Roongruedee Chaiteerakij (Chulalongkorn Univ., Thailand))

Åä·Ð 09¿ù 22ÀÏ ROOM 3 07:54~08:20 Discussion ()

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 09:30~09:50 HBV cccDNA: Mechanism of Its Formation and Therapeutic Targets Kyun-Hwan Kim(Sungkyunkwan Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 09:50~10:10 HBV Integration and Liver Cancer Thomas Tu(Univ. of Sydney, Australia)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 10:10~10:30 Genome Editing for cccDNA and Integrated HBV Jae Young Lee(ToolGen, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 10:50~11:05 Type I and III IFN Responses in Hepatitis Virus Infection Pil Soo Sung(The Catholic Univ. of Korea, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:05~11:20 T-Cell Responses and Immunopathogenesis of Viral Hepatitis Yuri Cho(National Cancer Center, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:20~11:35 Characteristics of B Cells in HBV-Infected Liver Ji Eun Oh(KAIST, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 11:35~11:50 Chronic Hepatitis and Liver Fibrosis in Humans Hideki Ueno (Kyoto Univ., Japan)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:20~13:35 Treatment of Chronic Hepatitis B: When and Whom? Jae Yoon Jeong (National Medical Center, Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:35~13:50 Diagnosis and Management of Hepatitis C Virus Infection Yun Chin Cho(Gyeongsang National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 13:50~14:05 Diagnosis and Management of Autoimmune Hepatitis Young Chang(Soonchunhyang Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 14:05~14:20 Surveillance and Diagnosis of HCC Han Ah Lee(Ewha Womans Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 14:40~15:00 Epidemiology, Natural History and Risk Stratification of NAFLD Yang Hyon Baek(Dong-A Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:00~15:20 Lifestyle Intervention and Available Medications in NAFLD Treatment Se Young Jang(Kyungpook National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:20~15:40 Management of Severe Alcoholic Hepatitis Tae Suk Kim (Kangwon National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 15:40~16:00 Updated Guideline on Drug-Induced Liver Injury Nae-Yun Heo (Inje Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 16:20~16:40 Diagnosis and Management of Ascites and Related Complications Chang Hun Lee(Jeonbuk National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 16:40~17:00 Diagnosis and Management of Acute Variceal Bleeding Seong Hee Kang(Korea Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 17:00~17:20 When Is the Appropriate Time for Liver Transplantation? Kwang Il Seo(Kosin Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 3 17:20~17:40 Treatment strategy based on HCC stage Jung Hwan Yu (Inha Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 4 07:30~07:42 Does Metabolic Derangement Corrected after Cure of HCV? Eun Ju Cho(Seoul National Univ., Korea)

±³À°½Ã°£ 09¿ù 22ÀÏ ROOM 4 07:42~07:54 Effects of DAA Treatment on Extrahepatic Manifestations in HCV Infection Hyun Phil Shin(Kyung Hee Univ., Korea)

Åä·Ð 09¿ù 22ÀÏ ROOM 4 07:54~08:20 Discussion Geum-Youn Gwak(Sungkyunkwan Univ., Korea)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ°£ÇÐȸ APASL STC 2023 DAY 2 : 2023-09-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023³â Á¦3ȸ ÆÄÁֽà ÀÇ»çȸ ¿¬¼ö±³À°(¸¸¼º±âħ, õ½ÄÄ¡·á) : 2023-09-22
´ÙÀ½±Û (¿Â¶óÀÎ) »ó±Þº´¿øÀ¸·Î ÀÇ·Ú°¡ ÇÊ¿äÇÑ µÎ°æºÎÁúȯ : 2023-09-21
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 41 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 37 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 32 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 33 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 32 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 63 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 19 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 30 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 26 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 28 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 27 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 25 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 26 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 29 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 31 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷